Protagenic Therapeutics, Inc. (PTIX) Balance Sheet
PTIX balance sheet, 2025
December 31, 2025 · U.S. dollars$2.1M assets = $6.8M liabilities + −$4.7M equity
Liabilities exceed assets: shareholders’ equity is negative (−$4.7M).
Both columns are drawn to the same scale: what PTIX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
PTIX financial health
Descriptive bands, not a rating. Fiscal 2025.
PTIX balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $3.2M2016 | $2.1M2025 | −4.3%/yr | |
| Total liabilities | $684,8572016 | $6.8M2025 | +29.1%/yr | |
| Shareholders’ equity | $2.5M2016 | −$2.4M2025 | — | |
| Cash & short-term investments | $3.1M2016 | $2.2M2025 | −3.7%/yr | |
| Total debt | $02016 | $3.2M2025 | — | |
| Net cash (debt) | $3.1M2016 | −$943,2632025 | −$4.0M | |
| Working capital | $2.5M2016 | −$4.5M2025 | −$7.0M | |
| Book value per share | $1.872016 | −$1.242025 | — | |
| Current ratio | 4.622016 | 0.342025 | −4.28 | |
| Debt / equity | 0.002016 | 0.052022 | +0.05 | |
| Shares outstanding | 1.3M2016 | 1.9M2025 | +4.3%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PTIX assets
PTIX liabilities and equity
PTIX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
PTIX balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $2.2M | $1.8M | $4.1M | $8.0M | $10.4M | $671,091 | $798,623 | $612,874 | $1.7M | $3.1M |
| Cash & equivalents | $2.2M | $1.8M | $1.3M | $215,189 | $541,171 | $671,091 | $798,623 | $362,486 | $399,687 | $3.1M |
| Short-term investments | — | $0 | $2.8M | $7.8M | $9.8M | $0 | $250,388 | $250,388 | $1.3M | $0 |
| Receivables | $41,523 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $1,074 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $43,794 | $44,398 | $144,025 | $56,939 | $688,667 | $208,156 | $43,354 | $83,399 | $94,542 | $60,417 |
| Total current assets | $2.3M | $1.9M | $4.2M | $8.0M | $11.1M | $879,247 | $841,977 | $696,273 | $1.8M | $3.2M |
| Property, plant & equipment (net) | $38,836 | $73,046 | $123,332 | $1,775 | $0 | $0 | $296 | $611 | $1,022 | $1,097 |
| Goodwill & intangible assets | $2.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $2.1M | $2.0M | $4.3M | $8.0M | $11.1M | $879,247 | $842,273 | $696,884 | $1.8M | $3.2M |
| Liabilities | ||||||||||
| Accounts payable | $2.0M | $102,962 | $113,802 | $155,486 | $278,957 | $141,860 | $163,029 | $10,048 | $10,965 | $13,400 |
| Short-term debt | $3.2M | — | — | $344,230 | $186,149 | — | — | $0 | $0 | $0 |
| Total current liabilities | $6.8M | $942,759 | $655,252 | $1.1M | $799,535 | $655,187 | $1.2M | $907,767 | $561,692 | $684,857 |
| Long-term debt | $0 | $0 | $0 | $0 | $318,433 | $1.4M | $279,370 | $0 | $0 | $0 |
| Lease obligations | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $1.0M | $0 | $0 | $0 | $52,365 | $161 | $0 |
| Total liabilities | $6.8M | $942,759 | $655,252 | $1.1M | $1.1M | $2.0M | $1.5M | $907,767 | $561,692 | $684,857 |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $195 | $725 | $444 | $434 | $1,722 | $1,036 | $1,026 | $1,026 | $1,026 | $1,026 |
| Retained earnings (deficit) | −$9.1M | −$36.3M | −$30.8M | −$25.8M | −$22.2M | −$17.7M | −$15.2M | −$13.4M | −$10.8M | −$8.6M |
| Treasury stock | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Accumulated other comprehensive income | −$220,006 | −$129,850 | −$113,546 | −$676,907 | −$248,349 | −$171,586 | −$172,364 | −$170,540 | −$167,805 | −$181,635 |
| Minority interest | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Total shareholders' equity | −$2.4M | $1.0M | $3.7M | $6.9M | $9.9M | −$1.1M | −$634,366 | −$210,883 | $1.2M | $2.5M |
| Key figures | ||||||||||
| Total debt | $3.2M | — | — | $344,230 | $318,433 | $1.4M | $279,370 | $0 | $0 | $0 |
| Net cash (debt) | −$943,263 | — | — | $7.6M | $10.1M | −$702,705 | $519,253 | $612,874 | $1.7M | $3.1M |
| Working capital | −$4.5M | $940,108 | $3.5M | $6.9M | $10.3M | $224,060 | −$355,292 | −$211,494 | $1.2M | $2.5M |
| Tangible book value | −$4.5M | $1.0M | $3.7M | $6.9M | $9.9M | −$1.1M | −$634,366 | −$210,883 | $1.2M | $2.5M |
| Book value per share | −$1.24 | $0.21 | $0.84 | $1.60 | $2.70 | −$0.44 | −$0.25 | −$0.08 | $0.48 | $1.87 |
| Shares outstanding | 1.9M | 4.9M | 4.3M | 4.3M | 3.7M | 2.6M | 2.6M | 2.6M | 2.6M | 1.3M |
| Current ratio | 0.34 | 2.00 | 6.41 | 7.18 | 13.83 | 1.34 | 0.70 | 0.77 | 3.17 | 4.62 |
| Quick ratio | 0.33 | 1.95 | 6.19 | 7.12 | 12.97 | 1.02 | 0.67 | 0.68 | 3.00 | 4.53 |
| Debt / equity | — | — | — | 0.05 | 0.03 | — | — | — | 0.00 | 0.00 |
| Equity / assets | −112.2% | 51.8% | 84.8% | 86.1% | 89.9% | −130.8% | −75.3% | −30.3% | 68.5% | 78.3% |
| Jun '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $565,985 | $2.2M | $2.7M | $4.1M | $872,960 | $1.8M | $1.1M | $924,596 | $2.4M | $4.1M | $5.3M | $6.0M |
| Cash & equivalents | $565,985 | $2.2M | $2.7M | $4.1M | $872,960 | $1.8M | $1.1M | $924,596 | $831,778 | $1.3M | $153,332 | $219,435 |
| Short-term investments | — | — | — | — | — | $0 | $0 | $0 | $1.6M | $2.8M | $5.1M | $5.8M |
| Receivables | $0 | $41,523 | $44,043 | $98,632 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $1,074 | $1,075 | $1,095 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $143,886 | $43,794 | $90,643 | $135,077 | $55,216 | $44,398 | $366,904 | $444,292 | $43,994 | $144,025 | $104,076 | $874,671 |
| Total current assets | $709,871 | $2.3M | $2.9M | $4.3M | $928,176 | $1.9M | $1.4M | $1.4M | $2.5M | $4.2M | $5.4M | $6.9M |
| Property, plant & equipment (net) | $6,244 | $38,836 | $51,407 | $63,979 | $60,474 | $73,046 | $85,618 | $98,189 | $110,761 | $123,332 | $55,982 | $1,595 |
| Goodwill & intangible assets | $2.1M | $2.1M | $2.1M | $2.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $1 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $2.1M | $2.1M | $2.1M | $6.5M | $988,650 | $2.0M | $1.5M | $1.5M | $2.6M | $4.3M | $5.4M | $6.9M |
| Liabilities | ||||||||||||
| Accounts payable | $999,690 | $2.0M | $1.6M | $2.1M | $165,247 | $102,962 | $108,635 | $93,457 | $108,950 | $113,802 | $243,524 | $158,172 |
| Short-term debt | — | $3.2M | $3.2M | $4.0M | — | — | — | — | — | — | $419,763 | $394,309 |
| Deferred revenue | — | — | — | — | — | — | — | — | — | — | −$44,283 | $39,181 |
| Total current liabilities | $1.1M | $6.8M | $9.7M | $10.5M | $1.1M | $942,759 | $789,320 | $674,559 | $446,095 | $655,252 | $1.3M | $1.5M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $1 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $1.1M | $6.8M | $9.7M | $10.5M | $1.1M | $942,759 | $789,320 | $674,559 | $446,095 | $655,252 | $1.3M | $1.5M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $182 | $195 | $195 | $186 | $54 | $725 | $481 | $447 | $444 | — | $434 | $434 |
| Retained earnings (deficit) | −$5.0M | −$9.1M | −$11.3M | −$10.5M | −$37.7M | −$36.3M | −$34.7M | −$34.1M | −$32.5M | −$30.8M | −$29.1M | −$27.7M |
| Accumulated other comprehensive income | −$342,009 | −$220,006 | −$221,172 | −$258,244 | −$129,861 | −$129,850 | −$130,248 | −$130,160 | −$86,767 | — | −$617,737 | −$586,461 |
| Total shareholders' equity | $1.7M | −$2.4M | −$4.7M | −$4.0M | −$88,329 | $1.0M | $719,007 | $792,518 | $2.1M | $3.7M | $4.2M | $5.4M |
| Key figures | ||||||||||||
| Total debt | — | $3.2M | $3.2M | $4.0M | — | — | — | — | — | — | $419,763 | $394,309 |
| Net cash (debt) | — | −$943,263 | −$433,601 | $83,180 | — | — | — | — | — | — | $4.9M | $5.6M |
| Working capital | −$362,743 | −$4.5M | −$6.8M | −$6.1M | −$148,803 | $940,108 | $633,389 | $694,329 | $2.0M | $3.5M | $4.1M | $5.4M |
| Tangible book value | −$356,499 | −$4.5M | −$6.8M | −$6.1M | −$88,329 | $1.0M | $719,007 | $792,518 | $2.1M | $3.7M | $4.2M | $5.4M |
| Book value per share | $0.95 | −$1.24 | −$2.54 | −$1.07 | −$0.02 | $0.16 | $0.16 | $0.18 | $0.48 | $0.83 | $0.96 | $1.25 |
| Shares outstanding | 1.8M | 1.9M | 1.8M | 3.7M | 3.7M | 6.5M | 4.5M | 4.4M | 4.4M | 4.4M | 4.3M | 4.3M |
| Current ratio | 0.66 | 0.34 | 0.29 | 0.41 | 0.86 | 2.00 | 1.80 | 2.03 | 5.53 | 6.41 | 4.20 | 4.60 |
| Quick ratio | 0.53 | 0.33 | 0.29 | 0.40 | 0.81 | 1.95 | 1.34 | 1.37 | 5.43 | 6.19 | 4.12 | 4.01 |
| Debt / equity | — | — | — | — | — | — | — | — | — | — | 0.10 | 0.07 |
| Equity / assets | 82.6% | −112.2% | −219.2% | −61.2% | −8.9% | 51.8% | 47.7% | 54.0% | 82.7% | 84.8% | 76.4% | 78.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 9, 2026); data from EODHD.
PTIX financial position
At the end of fiscal 2025 (December 31, 2025), Protagenic Therapeutics had total assets of $2.1 million (up 9.0% from a year earlier), total liabilities of $6.8 million and shareholders' equity of -$2.4 million. It held $2.2 million in cash and short-term investments against $3.2 million of debt, net debt of $0.9 million. Its current ratio was 0.34. In the latest quarter (ended June 30, 2026) total assets were $2.1 million and equity $1.7 million.
Related: PTIX income statement, PTIX cash flow statement, PTIX key metrics. See the PTIX stock overview for the latest quote and news.
PTIX balance sheet FAQ
What are Protagenic Therapeutics's total assets?
Protagenic Therapeutics reported total assets of $2.1 million at the end of fiscal 2025 (December 31, 2025), compared with $2.0 million a year earlier.
How much debt does Protagenic Therapeutics have?
Protagenic Therapeutics had $3.2 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was —.
How much cash does Protagenic Therapeutics have?
Protagenic Therapeutics held $2.2 million in cash and short-term investments at the end of fiscal 2025; with $3.2 million of debt that is net debt of $0.9 million.
What is Protagenic Therapeutics's book value?
Protagenic Therapeutics's shareholders' equity (book value) was -$2.4 million at the end of fiscal 2025, or −$1.24 per share.
What is Protagenic Therapeutics's current ratio?
Protagenic Therapeutics had current assets of $2.3 million and current liabilities of $6.8 million, a current ratio of 0.34 (current liabilities exceed current assets).
How much goodwill does Protagenic Therapeutics have?
Protagenic Therapeutics carried $2.1 million of goodwill and intangible assets, 98.2% of total assets, at the end of fiscal 2025.